Feb 18 (Reuters) - Australian biotech CSL Ltd (CSL) on Thursday reported a 45% rise in half-year profit, boosted by higher demand for its vaccines and blood plasma products.
Net profit after tax came in at $1.81 billion for the six months ended December, up from $1.25 billion last year.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$260.88 |
Change
-4.650(1.75%) |
Mkt cap ! $126.3B | |||
| Open | High | Low | Value | Volume |
| $263.90 | $265.00 | $260.88 | $240.8M | 916.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 69 | $260.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $261.00 | 1249 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| CSL (ASX) Chart |